Amgen Inc. (NASDAQ:AMGN) is one of the “14 Best Pharma Dividend Stocks to Buy in 2026.” The company has seen a 27% increase in stock value in 2025, driven by strong financial results. Revenue in the third quarter rose 12% to $9.6 billion, with key products like Repatha and Tezspire showing significant growth.

Despite potential biosimilar competition for denosumab, Amgen Inc. (NASDAQ:AMGN) remains optimistic. The company continues to invest in its pipeline, with programs like MariTide in phase 3 studies. Amgen’s steady financial performance has supported its dividend outlook, with a forward yield of around 3%.

Amgen Inc. (NASDAQ:AMGN) is a global biotechnology company that develops innovative medicines for serious illnesses. While the stock shows investment potential, some AI stocks may offer greater upside. Investors looking for undervalued AI stocks can explore opportunities that benefit from current economic trends.

For more investment opportunities, check out “10 Cash-Rich Stocks to Buy Now” and “15 Global Dividend Stocks to Diversify Your Portfolio.” Disclosure: None.

Read more at Yahoo Finance: Strong Results and Pipeline Momentum Power Amgen’s (AMGN) 2025 Rally